Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Evaluating Drug Regimens for High-Risk Prostate Cancer
Clinical Breakthroughs

Evaluating Drug Regimens for High-Risk Prostate Cancer

By Anna WilliamsApr 26, 2018
Share
Facebook Twitter Email
The clinical trial was led by Maha Hussain, MD, deputy director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
The clinical trial was led by Maha Hussain, MD, deputy director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Photo Credit: Andre LaCour

The addition of a chemotherapy drug to adjuvant hormone therapy did not improve survival for patients with high-risk prostate cancer after surgery, according to the findings of a new clinical trial.

The study, published in the Journal of Clinical Oncology, was led by Maha Hussain, MD, deputy director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology. The study was a National Cancer Institute/The Cancer Therapy Evaluation Program-funded intergroup trial.

Despite significant progress, prostate cancer remains the second leading cause of cancer death among American men. In order to improve survival, there has been interest in enhancing therapies for patients with cancer that is localized but still considered to be high-risk.

In the years prior to this study, a chemotherapy drug called mitoxantrone was approved by the FDA for the treatment of metastatic castration-resistant prostate cancer — an advanced form where the cancer has spread and no longer responds to hormone therapy.

In the current study, the investigators hypothesized that adding mitoxantrone to adjuvant hormone therapy would improve overall survival in men with localized prostate cancer who had received a radical prostatectomy — first-line surgery to remove the entire prostate gland — and also were at high risk of relapse.

The trial, which began in 1999, included close to 1,000 men with localized cancer who had undergone the surgery and had one or more high-risk factors. They were randomized to either receive two years of androgen-deprivation therapy (ADT) alone, or ADT with mitoxantrone plus prednisone (a steroid often administered in conjunction with chemotherapy).

After a median follow-up of 11.2 years, the investigators found that mitoxantrone did not improve overall survival for patients. Disease-free survival rates were also the same in both groups.

Furthermore, mitoxantrone was associated with a higher rate of leukemia, compared with ADT alone, and the chemotherapy group experienced twice the rate of deaths from other malignancies.

Since this trial, Hussain has also been an investigator on numerous other seminal clinical trials for prostate cancer. To learn more about Hussain, her research and her career, read a profile in Northwestern Medicine magazine.

Read more:

  • Exploring New Insights Into Prostate Cancer Treatment and Screening
  • Tracking Quality of Life During Prostate Cancer Treatment
  • Evaluating Active Surveillance in Prostate Cancer

The study was supported by the National Cancer Institute of the National Institutes of Health under Grants No. CA180888, CA180819, CA180820, CA180821, CA180801, CA180834, CA180830, CA189953, CA180835, CA128567, CA190002, CA180846, CA189860, CA189804, CA189856, CA189858, CA189808, CA180828, CA189872, CA189822, CA189853, CA189848, CA189971, CA189952, CA46282, CA46368, CA35192, CA11083, CA35119, CA45450, CA74647, CA35128, CA35262, CA68183, CA37981, CA22423, CA58686, CA04919, CA46136, CA76132, CA76447, CA46113, CA12644, CA16385, and CA58723. It was also supported in part by AstraZeneca Pharmaceuticals and Immunex Corporation (Amgen).

Cancer Research
Share. Facebook Twitter Email

Related Posts

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Comments are closed.

Latest News

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Calcium Channel Blockers May Improve Chemotherapy Response

Jun 21, 2022

Expanded Role for Calcium Channels in T-Cells

Jun 17, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220607_Feinberg Campus_0070
20220607_Feinberg Campus_0066
20220607_Feinberg Campus_0054
Northwestern University 2022. Photo by Jim Prisching
20220607_Feinberg Campus_0077
20220607_Feinberg Campus_0063
20220607_Feinberg Campus_0111
20220607_Feinberg Campus_0083
20220607_Feinberg Campus_0018
20220607_Feinberg Campus_0023
20220607_Feinberg Campus_0072 (2)
20220607_Feinberg Campus_0120

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.